TRINITY

TRINITY

Transplant Research Innovation — International Network — Data Initiative

Harmonizing clinical, histological, immunological, virological and molecular data from patient populations worldwide — to advance precision medicine in solid organ transplantation.

The TRINITY Dinner
in Denver

Date

21 Oct. 2026Biannual meeting

City

DenverColorado, USA

During

Kidney WeekAmerican Society of Nephrology

Investigators and partners met over dinner at ASN Kidney Week for the consortium's biannual meeting on network and project advances: results from the BK polyomavirus, recurrence (PRECISE-RGN) and early dd-cfDNA studies, the 2027 research roadmap, and a first-hand account from UT Southwestern Medical Center on joining TRINITY as a large Texas center.

Since 2025

4TRINITY meetings

Shared cohorts

22K+American patients

Published

4Peer-reviewed papers

01 · Prognostication Abstract visualization of an allograft survival risk model

Extended validation of the iBox system

A prognostic system for kidney allograft failure, integrating eGFR, proteinuria, histology and immunology. Already validated across seven countries and randomized trials; TRINITY extends it to new centers and populations, including North American and African-American validation cohorts.

8,683

Recipients · validation cohort

2,570

North American recipients

02 · Biomarker Donor-derived cell-free DNA strands over a kidney biopsy

Donor-derived cell-free DNA

A non-invasive biomarker of graft injury. TRINITY validates the dd-cfDNA model across cohorts and evaluates its association with Banff 2022 microvascular inflammation phenotypes and early post-transplant settings. A prospective, IRB-approved study of serial dd-cfDNA in the first month post-transplant is starting at five US centers, coordinated by Duke University.

7,103

Biopsies paired with dd-cfDNA

5,256

Recipients

03 · Virology BK polyomavirus particles and longitudinal viral-load curves

BK polyomavirus

One of the largest international BK cohorts in kidney transplantation — integrating viral loads with biopsy findings, dd-cfDNA and outcomes to identify risk factors and build progression-risk tools. Twenty-four centers in six countries study viral trajectories, clearance and rebound.

19,652

Recipients

315,549

BK viral loads

Centers

04 · Recurrence Histology montage of recurrent native kidney disease

Recurrence of native disease

An undercharacterized contributor to graft loss. Kidney transplant recipients made up only 0.3% of participants in recent pivotal trials of new native-disease drugs. The PRECISE-RGN study defines the natural history of recurrence across IgA nephropathy, FSGS, membranous and membranoproliferative disease, and tests proteinuria as a surrogate endpoint after transplant. Final analyses are expected in Q1 2027.

650

Biopsy-proven recurrences

19,351

Recipients

Join TRINITY.

Centers interested in joining, or contributing data to specific projects, are warmly invited to contact the coordinating team. Investigators may also propose new research projects aligned with the consortium's scientific priorities. TRINITY provides multicenter scientific coordination, support with IRB and data extraction, curation, quality control and statistics, and manuscript coordination.

Paris Institute for Transplantation
& Organ Regeneration (PITOR)
INSERM - Institut National de la Santé et de la Recherche Médicale
Assistance Publique – Hôpitaux de Paris
Université Paris Cité - UPC
75015 Paris, France

The TRINITY Dinner
in Denver

Highlights from previous TRINITY meetings

Moving transplant care from reactive management toward precision-guided surveillance.

An unprecedented scale of harmonized, real‑world evidence.